In this comprehensive review and meta-analysis of studies performed with drug-eluting
stents (DES) Hill and coworkers1 give a complete and detailed overview of this entire field …

We read with interest the systematic review on drug-eluting stents (DES) by Hill et al. 1 The
early data available indicate that DES reduce in-stent restenosis and major adverse cardiac …

Drug-eluting stents are a major breakthrough in cardiology, with the Cypher™(Cordis
Corporation) and Taxus™(Boston Scientific) stents preventing 60–70% of repeat coronary …

We agree with the main thrust of the argument in the recent article by Eriksson1 that long-
term clopidogrel treatment (8 and 12 months) confers a small, or at most modest, advantage …

Les manœuvres de revascularisation coronaire sont moins performantes chez les patients
diabétiques et, plus particulièrement, l'angioplastie percutanée est grevée d'un taux élevé …

Quatre grandes études, comportant une fraction significative de sujets diabétiques, ont
analysé les bénéfices du stent enrobé au sirolimus (rapamycine) par comparaison à un …

We thank Scheen and colleagues for their interest in our systematic review1 of drug-eluting
coronary artery stents (DES) and congratulate them on their success in obtaining largely …

RESUMO A trombose intra-stent, embora sendo uma complicação rara, tem conseqüências
geralmente catastróficas, com elevadas taxas de mortalidade hospitalar e de infarto agudo …